VEGF-C promotes the development of lymphatics in bone and bone loss

  1. Devon Hominick
  2. Asitha Silva
  3. Noor Khurana
  4. Ying Liu
  5. Paul C Dechow
  6. Jian Q Feng
  7. Bronislaw Pytowski  Is a corresponding author
  8. Joseph M Rutkowski
  9. Kari Alitalo
  10. Michael T Dellinger  Is a corresponding author
  1. UT Southwestern Medical Center, United States
  2. Texas A&M College of Dentistry, United States
  3. Eli Lilly and Company, United States
  4. Texas A&M College of Medicine, United States
  5. University of Helsinki, Finland

Abstract

Patients with Gorham-Stout disease (GSD) have lymphatic vessels in their bones and their bones gradually disappear. Here we report that mice that overexpress VEGF-C in bone exhibit a phenotype that resembles GSD. To drive VEGF-C expression in bone, we generated Osx-tTA;TetO-Vegfc double-transgenic mice. In contrast to Osx-tTA mice, Osx-tTA;TetO-Vegfc mice developed lymphatics in their bones. We found that inhibition of VEGFR3, but not VEGFR2, prevented the formation of bone lymphatics in Osx-tTA;TetO-Vegfc mice. Radiological and histological analysis revealed that bones from Osx-tTA;TetO-Vegfc mice were more porous and had more osteoclasts than bones from Osx-tTA mice. Importantly, we found that bone loss in Osx-tTA;TetO-Vegfc mice could be attenuated by an osteoclast inhibitor. We also discovered that the mutant phenotype of Osx-tTA;TetO-Vegfc mice could be reversed by inhibiting the expression of VEGF-C. Taken together, our results indicate that expression of VEGF-C in bone is sufficient to induce the pathologic hallmarks of GSD in mice.

Article and author information

Author details

  1. Devon Hominick

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    Competing interests
    No competing interests declared.
  2. Asitha Silva

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    Competing interests
    No competing interests declared.
  3. Noor Khurana

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    Competing interests
    No competing interests declared.
  4. Ying Liu

    Biomedical Sciences, Texas A&M College of Dentistry, Dallas, United States
    Competing interests
    No competing interests declared.
  5. Paul C Dechow

    Biomedical Sciences, Texas A&M College of Dentistry, Dallas, United States
    Competing interests
    No competing interests declared.
  6. Jian Q Feng

    Biomedical Sciences, Texas A&M College of Dentistry, Dallas, United States
    Competing interests
    No competing interests declared.
  7. Bronislaw Pytowski

    Eli Lilly and Company, New York, United States
    For correspondence
    bronek.pytowski@gmail.com
    Competing interests
    Bronislaw Pytowski, During preparation of the manuscript, B. Pytowski was an employee of Eli Lilly and continues to hold stock in the company.
  8. Joseph M Rutkowski

    Department of Medical Physiology, Texas A&M College of Medicine, College Station, United States
    Competing interests
    No competing interests declared.
  9. Kari Alitalo

    Wihuri Research Institute, University of Helsinki, Helsinki, Finland
    Competing interests
    Kari Alitalo, Reviewing editor, eLife.
  10. Michael T Dellinger

    Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, United States
    For correspondence
    michael.dellinger@utsouthwestern.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3315-4239

Funding

The Lymphatic Malformation Institute (Research Grant)

  • Michael T Dellinger

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Holger Gerhardt, Max Delbrück Centre for Molecular Medicine, Germany

Ethics

Animal experimentation: The animal experiments described in this manuscript were carried out in accordance with animal protocols (2014-0031 and 2016-101510) approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical Center.

Version history

  1. Received: December 13, 2017
  2. Accepted: March 22, 2018
  3. Accepted Manuscript published: April 5, 2018 (version 1)
  4. Version of Record published: April 17, 2018 (version 2)

Copyright

© 2018, Hominick et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,037
    views
  • 421
    downloads
  • 48
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Devon Hominick
  2. Asitha Silva
  3. Noor Khurana
  4. Ying Liu
  5. Paul C Dechow
  6. Jian Q Feng
  7. Bronislaw Pytowski
  8. Joseph M Rutkowski
  9. Kari Alitalo
  10. Michael T Dellinger
(2018)
VEGF-C promotes the development of lymphatics in bone and bone loss
eLife 7:e34323.
https://doi.org/10.7554/eLife.34323

Share this article

https://doi.org/10.7554/eLife.34323

Further reading

    1. Developmental Biology
    Zhimin Xu, Zhao Wang ... Yingchuan B Qi
    Research Article

    Precise developmental timing control is essential for organism formation and function, but its mechanisms are unclear. In C. elegans, the microRNA lin-4 critically regulates developmental timing by post-transcriptionally downregulating the larval-stage-fate controller LIN-14. However, the mechanisms triggering the activation of lin-4 expression toward the end of the first larval stage remain unknown. We demonstrate that the transmembrane transcription factor MYRF-1 is necessary for lin-4 activation. MYRF-1 is initially localized on the cell membrane, and its increased cleavage and nuclear accumulation coincide with lin-4 expression timing. MYRF-1 regulates lin-4 expression cell-autonomously and hyperactive MYRF-1 can prematurely drive lin-4 expression in embryos and young first-stage larvae. The tandem lin-4 promoter DNA recruits MYRF-1GFP to form visible loci in the nucleus, suggesting that MYRF-1 directly binds to the lin-4 promoter. Our findings identify a crucial link in understanding developmental timing regulation and establish MYRF-1 as a key regulator of lin-4 expression.

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics
    Samuel C Griffiths, Jia Tan ... Hsin-Yi Henry Ho
    Research Article Updated

    The receptor tyrosine kinase ROR2 mediates noncanonical WNT5A signaling to orchestrate tissue morphogenetic processes, and dysfunction of the pathway causes Robinow syndrome, brachydactyly B, and metastatic diseases. The domain(s) and mechanisms required for ROR2 function, however, remain unclear. We solved the crystal structure of the extracellular cysteine-rich (CRD) and Kringle (Kr) domains of ROR2 and found that, unlike other CRDs, the ROR2 CRD lacks the signature hydrophobic pocket that binds lipids/lipid-modified proteins, such as WNTs, suggesting a novel mechanism of ligand reception. Functionally, we showed that the ROR2 CRD, but not other domains, is required and minimally sufficient to promote WNT5A signaling, and Robinow mutations in the CRD and the adjacent Kr impair ROR2 secretion and function. Moreover, using function-activating and -perturbing antibodies against the Frizzled (FZ) family of WNT receptors, we demonstrate the involvement of FZ in WNT5A-ROR signaling. Thus, ROR2 acts via its CRD to potentiate the function of a receptor super-complex that includes FZ to transduce WNT5A signals.